导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.96% | 1466/4773 |
| 近一周 | -1.53% | 494/5462 |
| 近一月 | 0.73% | 505/5421 |
| 近一季 | -2.32% | 1229/5209 |
| 近半年 | -13.40% | 3844/4920 |
| 近一年 | 10.76% | 966/4366 |
| 近两年 | 46.91% | 1578/2954 |
| 近三年 | 31.11% | 1011/2253 |
| 成立以来 | 88.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
9.40% 90/4961 |
-6.45% 3699/5312 |
- - |
- - |
| 2025 | 16.67% 2424/4813 |
-1.82% 2788/3635 |
1.48% 2311/4076 |
10.19% 3316/4524 |
6.27% 366/4813 |
| 2024 | 17.64% 664/3463 |
7.50% 242/2808 |
1.45% 470/3014 |
10.23% 2638/3129 |
-2.14% 1972/3463 |
| 2023 | 0.50% 407/2656 |
13.13% 278/2280 |
1.05% 245/2385 |
-5.46% 1323/2515 |
-7.01% 2010/2655 |
| 2022 | -13.19% 319/2207 |
-8.30% 277/1919 |
5.29% 925/2016 |
-12.37% 698/2113 |
2.60% 884/2208 |
| 2021 | 16.35% 270/1822 |
5.01% 124/1255 |
5.13% 822/1330 |
6.51% 219/1466 |
-1.05% 1303/1822 |
| 2020 | 12.82% 808/1250 |
-12.46% 887/1028 |
0.59% 1000/1067 |
13.59% 314/1164 |
12.80% 433/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达中证国企一带一路ETF VS. 长安沪深300非周期A(740101) |